407 related articles for article (PubMed ID: 35437712)
1. Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
Tiwari P; Khan H; Singh TG; Grewal AK
Neurochem Res; 2022 Jul; 47(7):1830-1852. PubMed ID: 35437712
[TBL] [Abstract][Full Text] [Related]
2. Poly (adp-ribose) polymerase inhibitors as potential therapeutic agents in stroke and neurotrauma.
Komjáti K; Besson VC; Szabó C
Curr Drug Targets CNS Neurol Disord; 2005 Apr; 4(2):179-94. PubMed ID: 15857303
[TBL] [Abstract][Full Text] [Related]
3. Structure and function of poly(ADP-ribose) polymerase-1: role in oxidative stress-related pathologies.
Virág L
Curr Vasc Pharmacol; 2005 Jul; 3(3):209-14. PubMed ID: 16026317
[TBL] [Abstract][Full Text] [Related]
4. Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
Henning RJ; Bourgeois M; Harbison RD
Cardiovasc Toxicol; 2018 Dec; 18(6):493-506. PubMed ID: 29968072
[TBL] [Abstract][Full Text] [Related]
5. The therapeutic potential of poly(ADP-ribose) polymerase inhibitors.
Virág L; Szabó C
Pharmacol Rev; 2002 Sep; 54(3):375-429. PubMed ID: 12223530
[TBL] [Abstract][Full Text] [Related]
6. Caffeine metabolites are inhibitors of the nuclear enzyme poly(ADP-ribose)polymerase-1 at physiological concentrations.
Geraets L; Moonen HJ; Wouters EF; Bast A; Hageman GJ
Biochem Pharmacol; 2006 Sep; 72(7):902-10. PubMed ID: 16870158
[TBL] [Abstract][Full Text] [Related]
7. Poly(ADP-ribosyl)ation and stroke.
Chiarugi A
Pharmacol Res; 2005 Jul; 52(1):15-24. PubMed ID: 15911330
[TBL] [Abstract][Full Text] [Related]
8. A novel and potent poly(ADP-ribose) polymerase-1 inhibitor, FR247304 (5-chloro-2-[3-(4-phenyl-3,6-dihydro-1(2H)-pyridinyl)propyl]-4(3H)-quinazolinone), attenuates neuronal damage in in vitro and in vivo models of cerebral ischemia.
Iwashita A; Tojo N; Matsuura S; Yamazaki S; Kamijo K; Ishida J; Yamamoto H; Hattori K; Matsuoka N; Mutoh S
J Pharmacol Exp Ther; 2004 Aug; 310(2):425-36. PubMed ID: 15075382
[TBL] [Abstract][Full Text] [Related]
9. Poly(ADP-ribose) polymerase inhibitors.
Southan GJ; Szabó C
Curr Med Chem; 2003 Feb; 10(4):321-40. PubMed ID: 12570705
[TBL] [Abstract][Full Text] [Related]
10. Natural inhibitors of poly(ADP-ribose) polymerase-1.
Banasik M; Stedeford T; Strosznajder RP
Mol Neurobiol; 2012 Aug; 46(1):55-63. PubMed ID: 22476980
[TBL] [Abstract][Full Text] [Related]
11. Poly (ADP-Ribose) polymerase 1 and parthanatos in neurological diseases: From pathogenesis to therapeutic opportunities.
Xu X; Sun B; Zhao C
Neurobiol Dis; 2023 Oct; 187():106314. PubMed ID: 37783233
[TBL] [Abstract][Full Text] [Related]
12. Poly(ADP-ribose) polymerase inhibitors activate the p53 signaling pathway in neural stem/progenitor cells.
Okuda A; Kurokawa S; Takehashi M; Maeda A; Fukuda K; Kubo Y; Nogusa H; Takatani-Nakase T; Okuda S; Ueda K; Tanaka S
BMC Neurosci; 2017 Jan; 18(1):14. PubMed ID: 28095779
[TBL] [Abstract][Full Text] [Related]
13. Novel modulators of poly(ADP-ribose) polymerase.
Szabo C; Pacher P; Swanson RA
Trends Pharmacol Sci; 2006 Dec; 27(12):626-30. PubMed ID: 17055069
[TBL] [Abstract][Full Text] [Related]
14. Minocycline protects cardiac myocytes against simulated ischemia–reperfusion injury by inhibiting poly(ADP-ribose) polymerase-1.
Tao R; Kim SH; Honbo N; Karliner JS; Alano CC
J Cardiovasc Pharmacol; 2010 Dec; 56(6):659-68. PubMed ID: 20881608
[TBL] [Abstract][Full Text] [Related]
15. Detecting and Quantifying pADPr In Vivo.
Lamade AM; Chen Y; Johnson CJ; Bayır H; Clark RSB
Methods Mol Biol; 2023; 2609():23-42. PubMed ID: 36515827
[TBL] [Abstract][Full Text] [Related]
16. Ginsenoside Rd blocks AIF mitochondrio-nuclear translocation and NF-κB nuclear accumulation by inhibiting poly(ADP-ribose) polymerase-1 after focal cerebral ischemia in rats.
Hu G; Wu Z; Yang F; Zhao H; Liu X; Deng Y; Shi M; Zhao G
Neurol Sci; 2013 Dec; 34(12):2101-6. PubMed ID: 23463404
[TBL] [Abstract][Full Text] [Related]
17. PARP inhibitors: new partners in the therapy of cancer and inflammatory diseases.
Peralta-Leal A; Rodríguez-Vargas JM; Aguilar-Quesada R; Rodríguez MI; Linares JL; de Almodóvar MR; Oliver FJ
Free Radic Biol Med; 2009 Jul; 47(1):13-26. PubMed ID: 19362586
[TBL] [Abstract][Full Text] [Related]
18. Role of poly(ADP-ribose) polymerase 1 (PARP-1) in cardiovascular diseases: the therapeutic potential of PARP inhibitors.
Pacher P; Szabó C
Cardiovasc Drug Rev; 2007; 25(3):235-60. PubMed ID: 17919258
[TBL] [Abstract][Full Text] [Related]
19. [Role of PARP and protein poly-ADP-ribosylation process in regulation of cell functions].
Drel' VR; Shymans'kyĭ IO; Sybirna NO; Velykyĭ MM
Ukr Biokhim Zh (1999); 2011; 83(6):5-34. PubMed ID: 22364016
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.
Curtin NJ; Szabo C
Mol Aspects Med; 2013 Dec; 34(6):1217-56. PubMed ID: 23370117
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]